Outlook Therapeutics (NASDAQ:OTLK) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.
This is a breakdown of recent ratings and recommmendations for Outlook Therapeutics and Proteon Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
6.1% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 54.4% of Proteon Therapeutics shares are held by institutional investors. 11.5% of Outlook Therapeutics shares are held by company insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Outlook Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Earnings & Valuation
This table compares Outlook Therapeutics and Proteon Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Outlook Therapeutics||$3.09 million||28.36||-$30.09 million||N/A||N/A|
|Proteon Therapeutics||N/A||N/A||-$29.96 million||($2.13)||-1.40|
Proteon Therapeutics has lower revenue, but higher earnings than Outlook Therapeutics.
This table compares Outlook Therapeutics and Proteon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Proteon Therapeutics beats Outlook Therapeutics on 7 of the 10 factors compared between the two stocks.
About Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
About Proteon Therapeutics
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.